Результати пошуку - Yi‐Hsiang Huang
- Показ 1 - 20 результатів із 66
- На наступну сторінку
-
1
Gastrointestinal and liver manifestations in patients with COVID-19 за авторством I‐Cheng Lee, Teh‐Ia Huo, Yi‐Hsiang Huang
Опубліковано 2020Revisão -
2
-
3
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma за авторством Mir Lim, Magdalena Espinoza, Yi‐Hsiang Huang, Joseph W. Franses, Hao Zhu, David Hsiehchen
Опубліковано 2025Artigo -
4
A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues за авторством Yi‐Hsiang Huang, Chengxiao Liao, Zefeng Shen, Yitong Zou, Weibin Xie, Qinghua Gan, Yuhui Yao, Junjiong Zheng, Jianqiu Kong
Опубліковано 2024Artigo -
5
-
6
The oral microbiome in autoimmune diseases: friend or foe? за авторством Xiaoyan Huang, Xiang‐Yu Huang, Yi‐Hsiang Huang, Jiarong Zheng, Lu Ye, Zizhao Mai, Xinyuan Zhao, Li Cui, Shaohong Huang
Опубліковано 2023Revisão -
7
-
8
The effect of oropharyngeal colostrum administration on the clinical outcomes of premature infants: A meta-analysis за авторством Zhen Yan Fu, Chi Huang, Lei Lei, Li Cheng Chen, Wei Li, Jiao Zhou, Ming Tao, Ming Tao Quan, Yi‐Hsiang Huang
Опубліковано 2023Revisão -
9
Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis за авторством Yin-Chen Wang, Sien-Sing Yang, Chien–Wei Su, Yuan-Jen Wang, Kuei‐Chuan Lee, Teh‐Ia Huo, Han‐Chieh Lin, Yi‐Hsiang Huang
Опубліковано 2016Artigo -
10
-
11
-
12
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma за авторством Chi-Jung Wu, Pei‐Chang Lee, Ya‐Wen Hung, Chieh-Ju Lee, Chen‐Ta Chi, I‐Cheng Lee, Ming‐Chih Hou, Yi‐Hsiang Huang
Опубліковано 2022Artigo -
13
Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization за авторством Shu‐Yein Ho, Po‐Hong Liu, Chia-Yang Hsu, Yi‐Hsiang Huang, Jia‐I Liao, Chien–Wei Su, Ming‐Chih Hou, Teh‐Ia Huo
Опубліковано 2023Artigo -
14
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience за авторством Wen‐Chi Wu, Tzu-Yuan Lin, Ming‐Huang Chen, Yi‐Ping Hung, Chien‐An Liu, Rheun‐Chuan Lee, Yi‐Hsiang Huang, Yee Chao, San‐Chi Chen
Опубліковано 2022Artigo -
15
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma за авторством Pei‐Chang Lee, Yee Chao, Ming‐Huang Chen, Keng‐Hsin Lan, Chieh-Ju Lee, I‐Cheng Lee, San‐Chi Chen, Ming‐Chih Hou, Yi‐Hsiang Huang
Опубліковано 2020Artigo -
16
Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients за авторством Chien‐Wei Su, Yi‐Hsiang Huang, Teh‐Ia Huo, Hsuan Hui Shih, I‐Jane Sheen, Su–Wen Chen, Pui–Ching Lee, Shou–Dong Lee, Jaw‐Ching Wu
Опубліковано 2006Artigo -
17
Using Serum α-Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff? за авторством Chia‐Yang Hsu, Po‐Hong Liu, Yun-Hsuan Lee, Cheng‐Yuan Hsia, Yi‐Hsiang Huang, Han‐Chieh Lin, Yi‐You Chiou, Fa‐Yauh Lee, Teh‐Ia Huo
Опубліковано 2015Artigo -
18
Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients за авторством Yee Chao, Wing‐Kai Chan, MJ Birkhofer, OY-P Hu, S. S. Wang, Yi‐Hsiang Huang, Maiqi Liu, Jacqueline Whang‐Peng, K-H Chi, W‐Y Lui, S. D. Lee
Опубліковано 1998Artigo -
19
Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems за авторством Po‐Hong Liu, Chia‐Yang Hsu, Cheng‐Yuan Hsia, Yun-Hsuan Lee, Chien‐Wei Su, Yi‐Hsiang Huang, Fa‐Yauh Lee, Han‐Chieh Lin, Teh‐Ia Huo
Опубліковано 2015Artigo -
20
Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy за авторством Po‐Hong Liu, Chien–Wei Su, Chia‐Yang Hsu, Cheng‐Yuan Hsia, Yun-Hsuan Lee, Yi‐Hsiang Huang, Rheun‐Chuan Lee, Han‐Chieh Lin, Teh‐Ia Huo
Опубліковано 2016Artigo
Інструменти для пошуку:
Пов'язані теми
Medicine
Internal medicine
Hepatocellular carcinoma
Gastroenterology
Oncology
Cancer
Immunotherapy
Immunology
Virus
Biology
Hepatitis B virus
Nivolumab
Chemotherapy
Cohort
Confidence interval
Liver cancer
Adverse effect
HBsAg
Pathology
Disease
Hepatitis B
Hepatitis C
Surgery
Virology
Atezolizumab
Bevacizumab
Biochemistry
Hazard ratio
Intensive care medicine
Proportional hazards model